Deferred Tax Assets and Liabilities (CFA Level 1): Setting the Stage: The Difference Between Accounting and, Key Terms and Concepts, and Mechanics of DTAs and DTLs. Key definitions, formulas, and exam tips.
It’s funny: I remember the first time I tried to reconcile my company’s tax returns with our financial statements. I was sitting there thinking, “Wait, how can profit be different for accounting than it is for tax? Aren’t they the same thing?” Well, the truth is that you often get differences in how revenue and expenses are recognized, leading to something called deferred taxes. These “deferred” bits can show up either as assets (DTAs) or liabilities (DTLs), and they have significant implications for a company’s cash flow forecasts, equity valuations, and overall financial health.
Below, we’ll explore exactly how DTAs and DTLs arise, their impact on financial statements, and the key issues (and potential pitfalls) analysts should watch for.
At a high level, financial statements follow certain accounting standards (like IFRS or US GAAP), while tax returns follow tax laws and regulations set by jurisdictions. These two sets of rules aren’t always aligned. For instance, you might have an expense deducted immediately for tax purposes but capitalized and depreciated more slowly on the financial statements.
Over time, these timing differences create “temporary differences” between the carrying amounts of assets and liabilities in the financial statements and their tax bases in the tax returns. When these timing differences reverse in future periods, the effect on reported profit or loss also reverses. And that’s what leads to the recognition of deferred tax assets or liabilities.
Before diving deeper, let’s clarify a few core ideas:
You might also hear about permanent differences—discrepancies between accounting income and taxable income that never reverse (for example, fines or penalties that aren’t deductible for tax). However, permanent differences do not generate DTAs or DTLs because they never reverse.
DTAs and DTLs typically arise because of differences in revenue or expense recognition across accounting and tax regimes. Let’s break that down:
Picture a scenario where a company recognizes an expense on its financial statements before it is recognized for tax purposes (or recognizes revenue more slowly in the financial statements than for tax). As a result:
Hence, you get a DTA, which represents the future tax benefits the company can use to lower its taxes in subsequent periods. Another classic example is a net operating loss (NOL) carryforward: if a company has a big net operating loss in the current period, it may not fully use that loss this year, but it can apply it to reduce taxable income in future years. That potential future tax break is captured as a DTA.
Now flip the story. Suppose a firm uses an accelerated depreciation method for tax (which lowers taxable income today) but uses a slower method of depreciation on the financial statements (which results in relatively higher accounting income). This means:
Those future higher taxable profits imply higher future tax payments—hence, a DTL. It’s essentially the company’s deferral of current taxes, which will come due later.
Below is a simple Mermaid diagram to illustrate how we move from a temporary difference to a deferred tax position:
flowchart LR
A["Carrying Amount (Financial Reporting)"] --> B["Compare with Tax Base <br/>(Tax Reporting)"]
B --> C["Identify Temporary <br/>Difference"]
C --> D["Multiply by Enacted <br/>Tax Rate"]
D --> E["Determine <br/>DTA or DTL"]
When you open a company’s balance sheet, you might notice a line item for “Deferred Tax Assets” or “Deferred Tax Liabilities.” Depending on the size and trend:
Deferred taxes can influence liquidity and solvency ratios. For instance, a large DTL can understate the “true” degree of long-term obligations. A big DTA might overstate a firm’s solvency if the firm is unlikely to realize those future benefits (for example, if it’s consistently losing money).
Ask yourself: “Is the company truly going to earn enough profits to use this DTA?”
Under US GAAP, if it’s more likely than not (i.e., >50% probability) that part of the DTA won’t be realized, the company records a valuation allowance, which lowers the net DTA. In IFRS (IAS 12), a firm writes down the DTA if it’s no longer probable that the DTA can be fully realized—so the concept is similar, though the exact mechanics differ a bit. Either way, the key is that management relies on future projections of taxable income. If those projections are overly optimistic and never materialize, DTAs might get written down, causing a hit to earnings.
One of the most common DTAs stems from loss carryforwards. Suppose a company has a big loss this year—and the tax code allows that loss to be applied against profits in future years. The firm can record that potential tax shielding effect as a DTA. Here, you’ll definitely want to evaluate the firm’s track record and any near-term expiration of carryforward periods (e.g., in some jurisdictions, you can only carry losses forward for a certain number of years).
Imagine your friend starts a tech company that invests heavily in R&D. For the first two years, the company sees negative taxable income—so it builds up an NOL. That NOL could offset future profits once the product catches on. But what if the product flops? Well, then the DTA is less likely to be used, and you might see a big valuation allowance introduced or the DTA fully impaired.
Commonly, DTLs arise from depreciation differences (accelerated for tax vs. straight-line for financial statements), or from revaluations if, under IFRS, the company chooses the revaluation model for fixed assets. Another scenario might be intangible assets recognized for accounting purposes but not for tax until later.
Since many DTLs relate to depreciation, they often reverse over the asset’s life. However, some DTLs might remain on the books for a long time if the company continues reinvesting in new assets and using accelerated methods for tax. In practice, this can create an almost permanent deferral of tax payments—though eventually, if you stop purchasing new assets, the difference reverses.
Companies typically break down current and deferred tax components of their total income tax expense. They often provide a schedule showing major sources of DTAs and DTLs (e.g., “Accelerated depreciation,” “Pension obligations,” “NOL carryforwards,” etc.). In addition, many firms disclose a rate reconciliation from the statutory tax rate to the effective tax rate. This reconciliation can help you see how much of the difference is driven by deferred taxes, tax credits, foreign tax rate differentials, or other factors.
Reading these notes carefully can reveal:
When you build a financial model or do a multi-period valuation, you need to consider the expected reversal of DTAs and DTLs in your cash flow estimates. For instance, if a company is systematically deferring its taxes, its near-term free cash flow might be inflated. At some point, that tax deferral might catch up, reducing future cash flows.
Assessing the reversal patterns can be especially important in mergers, acquisitions, or significant restructurings. In such transactions, DTAs might be used to lower the combined company’s tax liability, which could boost the merger’s net present value. However, certain tax rules limit the usage of NOL carryforwards or other deferred tax benefits after a change in ownership.
Take a well-known manufacturing company that invests heavily in new equipment. If it applies an accelerated depreciation method for tax, the firm sees smaller taxable income now and, therefore, smaller current tax payments. Over many years, if the firm keeps renewing its equipment, its taxable income remains artificially lower than its accounting income, creating a growing DTL. Meanwhile, the stock might look very profitable from an accounting perspective, but you, as an analyst, should understand that some portion of the reported “savings” is just delayed rather than erased.
On the flip side, consider a pharma company that invests big time in R&D. Often, the intangible R&D costs are handled differently for tax and accounting. The mismatch can create a large DTA or DTL, depending on which recognition rules apply first. If the firm develops a blockbuster drug and profits soar, those DTAs can be used to offset future taxes. But if the firm’s pipeline fails, there might be a big write-down of the DTA, hitting the income statement and spooking the market.
If you’re wondering about deeper rule-based differences, see Section 8.10 in this same chapter. In broad strokes, IFRS is governed by IAS 12 for income taxes, and US GAAP by ASC 740. While the logic is similar, you’ll find nuances in language (e.g., “valuation allowance” vs. “probability test”), and certain disclosure requirements might differ. The fundamental concept, though—calculating a temporary difference and multiplying by an enacted tax rate—remains consistent.
Let’s walk through a very quick numeric example (the numbers are small, but the principle is the same for any magnitude):
Conversely, if you recognized an expense earlier for accounting than for tax, you’d get a DTA.
Deferred taxes might seem like a dull footnote, but they can radically reshape a company’s reported profits and future outlook. Whether you’re analyzing a startup’s carryforwards or a global manufacturer’s depreciation policies, pay close attention to how these balances are built, maintained, and ultimately reversed. And, of course, don’t be afraid to dive into the footnotes—that’s where you’ll find the real story of how a company’s future tax positions might unfold.
Important Notice: FinancialAnalystGuide.com provides supplemental CFA study materials, including mock exams, sample exam questions, and other practice resources to aid your exam preparation. These resources are not affiliated with or endorsed by the CFA Institute. CFA® and Chartered Financial Analyst® are registered trademarks owned exclusively by CFA Institute. Our content is independent, and we do not guarantee exam success. CFA Institute does not endorse, promote, or warrant the accuracy or quality of our products.